comprehensive -WSS

comprehensive

author：Wikipedia 2025-08-12 09:11:31 - browse：3384

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： Merck drug for rare lung condition set for approval in U.S.

leisure time

WSS

Drug repurposing or repositioning? The language matters

Supreme Court strikes down use of affirmative action

Vertex Pharmaceuticals may move headquarters in Boston

Supreme Court strikes down use of affirmative action

Readout LOUD podcast: mifepristone case, GLP

Food as medicine: Medically tailored meals may get standardized

knowledge

comprehensive

hotspot

Continuity nursing helped my family in our darkest PICU moments

Decaf coffee targeted by food safety group under obscure FDA rule

United colonoscopy coverage change 'may cost lives,' doctors say

Covid vaccine financial winners and losers, from Pfizer to Novavax

Apple is now the first public company to be valued at $3 trillion

Covid vaccine financial winners and losers, from Pfizer to Novavax

Wildfire smoke exposes gaps in outdoor worker protections

Virginia high school admissions case could be legal follow

At least 13 dead in Texas as scorching temps continue

Psychedelics group wrestles with new pharma identity

knowledge

Oprah kicked off a national conversation on obesity. Let's have it

BioMarin wins approval for gene therapy to treat hemophilia A

Readout LOUD podcast: mifepristone case, GLP

Scientists boost immune system in aging mice by making it youthful

Alkermes shareholders re

Readout Newsletter: WuXi and Congress, Boundless Bio, etc.

knowledge

leisure time

leisure time

knowledge